About this trial
Female patients diagnosed with lipedema will be divided into two groups based on their Pittsburgh Sleep Quality Index (PSQI) scores: PSQI ≤ 5 and PSQI \> 5. Age, body mass index (BMI), education level, menopausal status (reproductive period, perimenopausal period, postmenopausal period), number of births, duration of illness, occupation, marital status, disease stage, lipedema type, lower extremity functional scale, and the World Health Organization Quality of Life Scale - Short Form (Physical Health, Psychological Health, Social Relationships...)
Eligibility criteria
Qualifiers
Serum magnesium levels must have been measured within the past 6 month
Be at least 18 years of age
Have a diagnosis of lipedema based on the Wold criteria
Have no cognitive or mental health issues
Disqualifiers
No serum magnesium level measured within the past 6 months
Use of magnesium supplements for lipedema within the past 6 months, or the presence of any condition known to affect magnesium absorption or serum magnesium levels (e.g., use of a proton pump inhibitor [PPI] or diuretic)
The presence of other types of edema in which a component other than lipedema is predominant (e.g., lymphedema, venous edema, edema associated with heart or kidney failure, etc.)
A body mass index (BMI) of over 50.0 (this condition reflects severe obesity, which has a significant impact on health beyond lipedema alone)
Trial design
Treatments tested in this trial
- Magnesium